Table 2.
Characteristics of candidate tetravalent dengue vaccines in various phases of clinical trials
| Vaccine type | Manufacturer | Candidate vaccine | Candidate vaccine description | Clinical trial phase | Protective efficacy of vaccine |
|---|---|---|---|---|---|
| Attenuated chimera vaccine | (1) Sanofi-Pasteur | CYD-TVD | Recombinant DENV vaccine with yellow fever 17D vaccine strain as backbone and substitution of preM and E protein genes with each of the four DENV serotype | PIII | 56.5–60.8 % |
| (2) US-CDC/Inviragen/Takeda Pharmaceuticals | DENVax | Recombinant DENV vaccine with DENV-2 as backbone and substitution of preM and E protein genes of DENV-1, DENV-3, and DENV-4 | PII | –1 | |
| (3) NIAID | TetraVax-DV | Attenuated tetravalent formulation with a deletion of 30 nucleotides from 3′ UTR of DENV-1, DENV-3 (or chimeric DENV-3/DENV-4), DENV-4, and a chimeric DENV-2/DENV-4 | PII | – | |
| Attenuated vaccine | Mahidol University/Kaketsuken | – | Attenuated vaccine strains by serial passages in PDK cells | PII | – |
| Inactivated vaccine | WRAIR, GSK | TDENV-PIV | Whole purified inactivated vaccine | PI | – |
| Subunit vaccine | Merck (Hawaiian Biotech) | DENV-V180 | Truncated DENV E protein | PI | – |
| DNA vaccine | U.S. Army Medical Research and Material Command/WRAIR | TVDV | Plasmids encoding the prM/E genes of each DENV serotype | PI | – |
aIndicates no data